Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with concurrent chemoradiation followed by pembrolizumab with or without olaparib versus chemoradiation alone in newly diagnosed limited-stage small cell lung cancer
2023-504959-27-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and olaparib in small cell lung cancer (SCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Planned start Dec 2023; status: authorised.
02
Drugs
pembrolizumabolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-504959-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504959-27-00.